Em geral, a substncia no tem potencial de causar alergia
However, this phenomenon is rather a restoration of the first-phase insulin response due to the concomitant weight loss of typically 56 kg
This success led to the development of exenatide, the first GLP-1 receptor agonist approved by the FDA for the treatment of diabetes (in 2004)
Slower gastric emptying reduces fluid absorption consistency
Section 503A permits compounding of drug products as customized therapies for identified individual patients whose medical needs cannot be met by commercially available drug products. 503B compounding , on the other hand, is performed at outsourcing facilities, which are subject to stricter FDA oversight, including cGMP requirements, a requirement to register with FDA, periodic FDA inspections and an obligation to submit adverse event reports and other product-specific information to FDA
10.1002/ejhf.240 77 SaponaroF.SonaglioniA.RossiA.MontefuscoL.LombardoM.AddaG.et al (2016)
